T-Cell Lymphoma Clinic Trials

submitted by: mdanderson

Our mission is to improve the cure rate of patients with PTCL and reduce treatment-related toxicity by developing novel targeted therapy using rationally designed small molecules, antibodies and combination regimens of biologic agents.

For referrals, please contact ayounes@mdanderson.org or Amanda Copeland at ARCopeland@mdanderson.org.

A Team Approach for Treating T-Cell Lymphoma

submitted by: mdanderson
Of the approximately 76,000 new patients who will be diagnosed with non-Hodgkin lymphoma (NHL) this year, 15% will have peripheral T-cell lymphoma (PTCL). To meet these challenges, we've assembled a world-class team of medical oncologists, dermatologists, radiation therapists, hematopathologists and stem cell transplant experts to create a multidisciplinary T-cell lymphoma working group. Chaired by Younes, the group discusses challenging cases and recent clinical and pre-clinical data in...

Treating Lymphoma - Dr. Frederick Hagemeister

submitted by: mdanderson

http://bit.ly/kG2BS3 Lymphoma is the fifth most common cancer and the second fastest growing cancer. Dr. Frederick Hagemeister believes that during treatment, patients should maintain as normal a level of activity as possible to help with the treatment process.

Identification and Regulation of c-Myb Target Genes in MCF-7 cells.

submitted by: aquintan
BACKGROUND: The c-Myb transcription factor regulates differentiation and proliferation in hematopoietic cells, stem cells and epithelial cells. Although oncogenic versions of c-Myb were first associated with leukemias, over expression or rearrangement of the c-myb gene is common in several types of solid tumors, including breast cancers. Expression of the c-myb gene in human breast cancer cells is dependent on estrogen stimulation, but little is known about the activities of the c-Myb...
Authors: Anita m. Quintana, Fan Liu, John p. O'rourke, Scott a. Ness

The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers

submitted by: BernardFriedenson
Background The present study was designed to test the hypothesis that inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias. In people who do not have BRCA1 or BRCA2 gene mutations, the encoded proteins prevent breast/ovarian cancer. However BRCA1 and BRCA2 proteins have multiple functions including participating in a pathway that mediates repair of DNA double strand breaks by error-free...
Authors: Bernard Friedenson